Insider plans 4,533-share Zevra Therapeutics (ZVRA) Rule 144 stock sale

Rhea-AI Filing Summary

ZVRA filed a notice for a planned insider stock sale under Rule 144. The person named in the filing intends to sell 4,533 shares of Zevra Therapeutics common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of $40,162.38 on the NASDAQ.

The shares are being sold after acquisition as restricted stock units on 01/30/2026. Zevra Therapeutics had 56,297,535 common shares outstanding, which is a baseline figure for the company’s equity.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	4533	40162.38	56297535	01/30/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	01/30/2026	Restricted Stock Units	Issuer			4533	01/30/2026	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the ZVRA Form 144 filing disclose?

The Form 144 discloses a proposed sale of 4,533 shares of Zevra Therapeutics common stock. The shares are to be sold under Rule 144 through Morgan Stanley Smith Barney LLC on NASDAQ, with an aggregate market value of $40,162.38 based on the filing details.

How many ZVRA shares are planned to be sold in this Form 144?

The filing indicates an intended sale of 4,533 shares of Zevra Therapeutics common stock. These shares were acquired as restricted stock units and are being registered for potential resale under Rule 144 through a broker on the NASDAQ exchange.

What is the aggregate market value of the ZVRA shares in this Form 144?

The aggregate market value of the planned 4,533-share sale is reported as $40,162.38. This figure reflects the total market value of the securities covered by the notice at the time the Rule 144 filing was prepared for Zevra Therapeutics common stock.

How and when were the ZVRA shares in this Form 144 acquired?

The 4,533 Zevra Therapeutics shares were acquired on 01/30/2026 through restricted stock units. The filing lists the issuer as the source of the shares, with the same date shown for both acquisition and payment, and describes the nature of payment as “N/A.”

What does the Form 144 say about ZVRA shares outstanding?

The notice states that 56,297,535 shares of Zevra Therapeutics common stock were outstanding. This number serves as a baseline figure for the company’s total common shares when comparing the planned 4,533-share Rule 144 sale to the broader equity base.

Which broker and exchange are involved in the ZVRA Form 144 sale?

The filing lists Morgan Stanley Smith Barney LLC Executive Financial Services as the broker for the transaction. The common shares of Zevra Therapeutics covered by this Rule 144 notice are intended to be sold on the NASDAQ stock exchange, according to the document.